This company is a reverse merger and research and development play. Everyone knows that. There is no income here. Right now we are all investing in the intellectual property but you know this already.
Once the NIH funds these awesome trials, it's on. I expect a Buyout personally as that is how a lot of these go. I can also see them staying ENZC and licensing these proprietary methods to all the different therapy's it can be added to. Which seems to be the whole health spectrum.
News 
Market Data 
Discover 
